Koru Pharma Launches AVALON Clinical Trials in China

Koru Pharma is taking a significant step forward in solidifying its presence in Asia’s largest market by initiating clinical trials for our cross-linked hyaluronic acid filler, “AVALON ,” in China.

On June 9th, 2024, CEO Roman Vernidub, confirmed the proceeding of these pivotal clinical trials at four local hospitals, including the renowned Shanghai Tongji University Hospital. This effort aims to secure approval from China’s National Medical Products Administration (NMPA). Currently, the bioethics committee (IRB) approval process is progressing smoothly across all participating hospitals, setting the stage for the comprehensive clinical trial. The preliminary procedures are estimated to be finalised by July, with the full clinical trial expected to conclude by 2026 after approximately one year of testing.

Simultaneously, Koru Pharma is carrying out confirmatory clinical trials in Korea. The recruitment of subjects plan to be finalised by June and the domestic trials by June of next year. Leveraging the clinical data obtained from these trials, we aim to expedite our entry into the global market, starting with obtaining domestic and European CE certifications.

Founded in 2016, Koru Pharma has rapidly positioned itself at the forefront of K-beauty exports. Our extensive sales network spans approximately 120 countries, including 41 in Europe, with major products such as Dermal Fillers and Skin Boosters. Our ongoing mission is to become the No. 1 Health Care & Beauty company by showcasing the competitiveness of K-beauty and pioneering next-generation fillers without crosslinking agents.

Source:  https://www.pharmnews.com/news/articleView.html?idxno=247061